



Concise Review: Extracellular Vesicles Overcoming Limitations of Cell Therapies in Ischemic Stroke

THORSTEN R. DOEPPNER ,^a MATHIAS BÄHR,^a DIRK M. HERMANN,^{b*} BERND GIEBEL^{c*}

Key Words. Stem/progenitor cell • Stem cell transplantation • Nervous system • Neural differentiation • Mesenchymal stem cells

^aDepartment of Neurology, University Medical Center Goettingen, Goettingen, Germany; ^bDepartment of Neurology; ^cInstitute for Transfusion Medicine, University of Duisburg-Essen Medical School, Essen, Germany

*Contributed equally.

Correspondence: Thorsten R. Doeppner, M.D., Department of Neurology, University Medical Center Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany. Telephone: 49 551 39 66660; e-mail: thorsten.doeppner@med.uni-goettingen.de; or Bernd Giebel, Ph.D., Institute for Transfusion Medicine, University of Duisburg-Essen Medical School, Hufelandstr. 55, 45145 Essen, Germany. Telephone: 49 201 723 4204; e-mail: bernd.giebel@uk-essen.de

Received April 3, 2017; accepted for publication September 5, 2017; first published September 23, 2017.

<http://dx.doi.org/10.1002/sctm.17-0081>

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

ABSTRACT

Despite recent advances in stroke therapy, current therapeutic concepts are still limited. Thus, additional therapeutic strategies are in order. In this sense, the transplantation of stem cells has appeared to be an attractive adjuvant tool to help boost the endogenous regenerative capacities of the brain. Although transplantation of stem cells is known to induce beneficial outcome in (pre-clinical) stroke research, grafted cells do not replace lost tissue directly. Rather, these transplanted cells like neural progenitor cells or mesenchymal stem cells act in an indirect manner, among which the secretion of extracellular vesicles (EVs) appears to be one key factor. Indeed, the application of EVs in preclinical stroke studies suggests a therapeutic role, which appears to be noninferior in comparison to the transplantation of stem cells themselves. In this short review, we highlight some of the recent advances in the field of EVs as a therapeutic means to counter stroke. *STEM CELLS TRANSLATIONAL MEDICINE* 2017;6:2044–2052

SIGNIFICANCE STATEMENT

Despite recent success in therapeutic approaches against stroke, especially in the field of endovascular therapy, additional therapeutic means are still in order. In this sense, the application of extracellular vesicles might be an interesting tool to induce post-ischemic neuroregeneration, overcoming the limitations and risks of stem cell transplantation themselves.

STATE-OF-THE-ART STROKE TREATMENT

Ischemic stroke treatment currently involves three concepts: The admission of stroke patients to stroke units, the application of thrombolytics, and the recanalization of the occluded vessel by endovascular clot removal [1–4]. With the first stroke units being introduced in the 1990s, stroke management has turned from a purely observational field toward an evidence based therapeutic field. Controlled randomized studies not only demonstrated the utility of the thrombolytic recombinant tissue plasminogen activator to improve stroke outcome when administered intravenously within 4.5 hours after symptom onset [5], but more recently revealed the efficacy of endovascular recanalization therapy [1, 2]. Despite this great success, the majority of patients receive none of the two aforementioned treatments, partially because of narrow time windows or because of significant complication risks. This justifies the need for additional treatments, which alleviate the long-term consequences of a stroke.

POST-STROKE BRAIN REPAIR

With strategies on brain protection having failed in clinics in the 1980s and 1990s, current

preclinical research strongly focuses on promoting the regenerative capacities of the ischemic brain. The physiological basis of the latter is the persistence of endogenous neurogenesis in the adult mammalian brain within so called stem cell niches, namely the subventricular zone (SVZ) of the lateral ventricles [6–8] and the subgranular zone of the dentate gyrus [9, 10]. Upon stroke, neural progenitor cells (NPCs) within the SVZ migrate toward the ischemic lesion site where they proliferate [11, 12]. Yet, the stroke-induced promotion of post-stroke neurogenesis has restricted functional relevance, as new-born cells show both low survival rates and poorly differentiate into mature neurons [13–15].

In order to use the endogenous regenerative potential of the ischemic brain, two different strategies to manipulate neurogenesis are under investigation: (a) enhancing the resistance of NPCs to delayed degeneration and (b) augmenting the number of NPCs in the ischemic brain tissue. The former can be achieved by the administration of antiapoptotic drugs [14, 16], the latter is thought to be accomplished by stimulating NPC proliferation or by transplantation of exogenous NPCs. Although transplantation of

Table 1. Preclinical studies and clinical trials on systemic post-stroke delivery of MSCs and NPCs

Species	Cell type	Delivery timing	Key results	References
Mouse	Umbilical cord MSCs	Within 30 minutes	Reduction of brain injury & modulation of TGF expression	[23]
Rat	Adipose-derived MSCs	Within 24 hours	Reduction of brain injury/improved motor coordination	[24]
Rat	Adipose-derived MSCs (i.ventr./i.v./i.a.)	Within 24 hours	Reduction of brain injury/improved motor coordination	[25]
Rat	BM-derived MSCs	Up to 1 month	Increased angiogenesis and better neurological recovery	[26]
Rat	Placenta-derived MSCs	24 hours versus 8 + 24 hours	increased neurological recovery	[27]
Rat	BM-derived MSCs (i.a.)	d2 and d7	Increased angiogenesis and homing/no effect on neurological recovery	[28]
Rat	BM-derived MSCs	3 hours	Reduction of brain injury/improved functional outcome	[29]
Rat	BM-derived MSCs	24 hours	Increased angiogenesis	[30]
Rat	NPCs (i.a./i.v./i.c.)	24 hours	Migration and distribution patterns depend on delivery routes	[31]
Mouse	NPCs	d7	Reduced brain injury/improved neurological recovery	[32]
Mouse	NPCs	6 hours	Improved neurological recovery	[33]
Mouse	NPCs	Up to 1 month	Reduced brain injury/increased tissue regeneration/improved functional recovery	[34]
Mouse	NPCs (i.v./i.a./i.s./i.ventr./i.cort.)	6 hours (i.v.)	Sustained reduction of brain injury after systemic transplantation	[35]
Rat	NPCs	24 hours	Reduced tissue injury and better neurological score	[36]
Human Phase II	Adipose-derived MSCs	Within 2 weeks	Recruiting patients	[37]
Human Phase I/II	BM-derived MSCs (i.a.)	Between 5–9 days	No safety concerns/no better outcome after 6 months	[38]
Human	BM-derived MSCs	Within 1 week after randomization	No safety concerns/better outcome for some scores	[39]
Human	BM-derived MSCs	36–133 days post-stroke	No safety concerns within 1 year	[40]
Human	BM-derived MSCs	3–12 months post-stroke	No safety concerns within 24 weeks	[41]
Human	BM-derived MSCs	3–24 months post-stroke	No safety concerns within 24 weeks/improved Barthel index	[42]

This list is not intended to be complete. It reflects a selection of representative studies where MSCs or NPCs have been applied systemically after stroke, that is, intravenously (if not stated otherwise) or intraarterially. Studies using stereotactic transplantation are excluded.

Abbreviations: BM, bone marrow; i.a., intraarterial delivery; i.c., intracisternal delivery; i.cort., intracortical delivery; i.v., intravenous delivery; i.ventr., intraventricular; MSCs, mesenchymal stem cells; NPCs, neural progenitor cells; TGF, transforming growth factor.

stem cells improves post-stroke symptoms, grafted stem cells do not replace cells lost in injured tissue. Rather, grafted stem cells act in an indirect manner, very likely by releasing trophic and anti-inflammatory factors that promote the survival, remodeling, and plasticity of the ischemic brain tissue [17–19].

Considering the paracrine nature of stem cell-mediated beneficial effects, the choice of stem cell source might not be essential for achieving recovery-promoting effects of cellular therapeutics. As a matter of fact, in addition to NPCs stem cells derived from various adult tissues have been found to promote restorative effects in the ischemic brain [18, 20–22]. Especially due to their broad availability, their simple handling and their low side effects, bone marrow-derived mesenchymal stem cells (MSCs) became an attractive cell source to treat ischemic stroke in a number of different preclinical models.

TRANSPLANTATION OF MSCs AND NPCs AFTER STROKE

Preclinical transplantation studies in a plethora of stroke models using MSCs or NPCs have shown beneficial effects (Table 1) in a large number of different readouts [23, 26–36, 43–45]. NPCs,

either administered intracerebrally or systemically, mediate neuroprotection and enhance neurological recovery via stimulation of endogenous angiogenesis and neurogenesis. The mechanisms involved in the process of NPC-induced brain protection and brain regeneration greatly depend on both cell delivery routes and cell delivery timing [34, 35]. For example, acute NPC transplantation reduced neuronal injury and infarct volume, while transplantation at later stages rather modifies post-stroke brain regeneration and neuronal plasticity.

Likewise, the transplantation of MSCs, which have been administered systemically in the majority of studies, revealed promising effects in experimental stroke models. MSC transplantation was found to reduce neuronal injury and infarct volume, increase angiogenesis and neurogenesis, and improve neurological recovery. Although a majority of studies has been performed on BM-derived MSCs, some studies imply the application of adipose-derived MSCs which might appear to be an attractive cell type as well [24, 25], since the latter is easy to obtain. Due to their beneficial effects in the preclinical models, controlled randomized clinical trials (Table 1) using MSCs (and to a lesser extent NPCs as well) for stroke treatment have been started [38–40, 46]. Although patient recruitment is so far low, which precluded more

final conclusions from these studies, some studies reported beneficial outcomes after MSC transplantation. Of note, no clinically relevant side effects within the observation periods of maximal 5 years have been observed.

At the mechanistic level, it was initially proposed that applied MSCs enter the damaged tissue and replace lost cell types. However, in preclinical stroke as well as in other disease models, MSCs are hardly detected in affected tissues [47–52]. Most of systemically applied MSCs get trapped within the lungs [53, 54]. Due to these observations, the initial idea that MSCs can replace cells in affected tissues or directly interact with target cells became challenged, and the hypothesis emerged that MSCs effectively act in a paracrine rather than a cellular manner [55].

STRUCTURE OF EXTRACELLULAR VESICLES AND BIOLOGICAL PROPERTIES

Whereas early studies proposing a paracrine mode of action of administered MSCs claimed that soluble factors, such as growth factors or cytokines, mediate the stem cells' beneficial therapeutic effects [47]; more recent data qualified extracellular vesicles (EVs) as the critical agents [56]. Indeed, MSC-derived EVs (MSC-EVs) mediating therapeutic activities have been documented in a variety of different preclinical models and in a GvHD patient as well [49, 56–59].

EVs are released by almost all cell types and are detected as membrane-surrounded vesicles in all body fluids [60]. According to their origin, different EV types can be discriminated [61]. Exosomes are derivatives of the late endosomal compartment and have diameters of 70–150 nm. They correspond to intraluminal vesicles (ILVs) that are formed by the inward budding of the limiting membrane of sorting and late endosomes. The ILV containing endosomes are called multivesicular bodies (MVBs) or multivesicular endosomes. At the example of maturing reticulocytes, it has been shown that MVBs can fuse with the plasma membrane and release their ILVs as exosomes into the extracellular compartment [62–64]. In contrast, microvesicles (MVs), which have diameters of 100–1,000 nm, are formed as bud offs of the plasma membrane; together with apoptotic bodies which have said sizes of 500 nm to several micrometers, exosomes and MVs form the most prominent EV subtypes [65].

EVs contain specific molecular signatures reflecting their cell of origin [60, 66, 67]. Apart from lipids and proteins, metabolites and nucleic acids are recovered in prepared EV fractions [68–70]. A proportion of EVs might contain molecules that cells cannot metabolize, which are released into the extracellular environment for further processing. Other EVs seem to be assembled in a tailored manner to act as intercellular communication vehicles mediating complex signal exchanges between cells within and between different organs [60, 61, 71].

PRECLINICAL STUDIES USING EVs IN ANIMAL MODELS UNRELATED TO ISCHEMIA

In recent years, EVs have made a tremendous progress in biomedical research. At first, EVs were considered as debris. In 1996, however, Raposo and colleagues showed that B cells release MHC-II containing EVs which can activate T cells [72]. Yet, until the finding that EVs contain RNAs, in 2006 and 2007 [68, 70], EV research was sparse. Thereafter, the EV field started to grow exponentially.

Positive therapeutic effects of MSC-EVs were reported for the first time in 2009; the group of Giovanni Cammussi described EV-mediated therapeutic activities in a kidney failure model [59]. In 2010, the group of Sai Kiang Lim and Dominique de Kleijn discovered cardioprotective activities in their MSC-EV fractions [49]. We were the first group who applied MSC-EVs to a human patient in an individual treatment attempt. We applied an allogeneic MSC-EV fraction to a steroid refractory graft-versus-host disease patient, who failed to react on several second side strategies. Remarkably, the clinical symptoms declined significantly during and after the 2-week MSC-EV therapy, without revealing any side effects [57]. Meanwhile, EVs have been applied to several preclinical diseases models unrelated to ischemia, with some of them mentioned in Table 2.

The therapeutic benefit of EVs has been analyzed in various disease conditions, including inflammatory processes and cancer models. Similar to stem cells derived from different tissues, stem cell derived EVs exert multiple effects on different target cells. Similar to stem cells derived from different tissue sources inducing a variety of actions in biological tissues, EVs depending on their stem cell source have multiple effects on target cells, which may show overlaps, but also differences between cell sources. The latter is vital in understanding the different beneficial effects that EVs can yield. As such, EVs from a certain cell might show beneficial effects in a variety of malignant diseases, such as hepatocellular carcinoma, gastric cancer, or brain tumor, but not be equivalent in their cellular actions. Although a direct comparison between these studies is not eligible due to different study designs, EVs might either have a direct impact on tumor formation or enhance sensitivity to chemotherapy [75, 84, 86, 96]. Similar evidence for overlapping effects of EVs came from studies in inflammatory/infectious conditions, such as arthritis, hepatitis C, HIV, and sepsis [74, 87, 93, 98, 99]. One has to stress that several observations are still limited to *in vitro* research only. Particularly important from the authors' point of view, EVs have successfully been used in preclinical neurodegenerative disease models, such as amyotrophic lateral sclerosis and Parkinson's disease, as well as in myasthenia gravis where EVs were found to modulate inflammatory responses and cell survival [73, 82, 88]. Further evidence for a role of EVs in modulating inflammatory responses and tissue regeneration was found in animal models of traumatic brain injury and skin wounds [91, 92].

PRECLINICAL STUDIES USING EVs IN ANIMAL MODELS ASSOCIATED WITH ISCHEMIA

More recent studies identified the therapeutic efficacy of EVs in experimental conditions mimicking peripheral limb, heart or brain ischemia, that is, in models of peripheral occlusive artery disease, myocardial infarction and stroke (Table 3). For myocardial ischemia, the therapeutic efficacy of EVs has been shown in a large number of *in vitro* and *in vivo* studies [49, 101–111]. Thus, EVs from various cell sources including MSCs and embryonic stem cells, promoted cellular survival, reduction of infarct size, and stimulated myocardial remodeling and angiogenesis. Of note, these EV actions were associated with functional recovery evaluated by ejection fraction.

To the best of the authors' knowledge, six different studies have examined effects of EVs in ischemic stroke models, most in rats and one in mice [112–114, 116–118]. In the first rat study,

Table 2. Therapeutic application of EVs in preclinical disease models unrelated to ischemia

Disease condition	In vitro/in vivo	EV source	Key results	References
Amyotrophic lateral sclerosis	In vitro	Adipose-derived stem cells	Alleviation of SOD1 and mitochondrial dysfunction	[73]
Hepatitis C	In vitro	Umbilical MSCs	Antiviral activity by microRNA transport	[74]
Cancer therapy	In vivo (mice)	Modified melanoma cells	Suppression of tumor growth	[75]
Osteochondral disease	In vivo (rats)	Embryonic MSCs	Increased cartilage repair	[76]
Head and neck cancer cells	In vitro	(Ir)radiated head and neck cancer cells	Increased survival of irradiated tumor cells	[77]
Chemotherapy-induced POF	In vitro/in vivo (mice)	Amniotic fluid stem cells	Prevention of ovarian follicular atresia	[78]
Diabetic nephropathy	In vivo (rats)	Human urine-derived stem cells	Increased cell survival/vascular regeneration	[79]
Osteoporosis	In vitro/in vivo (rats)	Human-induced pluripotent stem cell-derived MSCs	Enhanced bone regeneration	[80]
Endothelial regeneration	In vitro	EPCs	Increased re-endothelialization	[81]
Myasthenia gravis	In vivo (rats)	Atorvastatin-modified BM-derived DCs	Suppression of immune responses	[82]
Traumatic brain injury	In vivo (mice)	MSCs	Reduced inflammation and cognitive impairment	[83]
Hepatocellular carcinoma	In vitro/in vivo (rats)	Modified adipose tissue-derived MSCs	Increased sensitivity to chemotherapy	[84]
Experimental colitis	In vivo (rats)	MSCs	Attenuation of inflammation	[85]
Gastric cancer	In vitro	MSCs	Increased drug resistance	[86]
Arthritis	In vivo (mice)	Bovine milk	Diminished cartilage pathology/reduced inflammation	[87]
Parkinson's disease	In vitro	Dental pulp stem cells	Reduced apoptosis	[88]
Carrageenan-induced inflammation	In vivo (mice)	Human dental pulp stem cells	Suppressed inflammation	[89]
Skin burn	In vitro/in vivo (rats)	Human umbilical cord MSCs	Increased angiogenesis in wounded tissue	[90]
Cutaneous wounds	In vivo (rats)	Human induced pluripotent stem cell-derived MSCs	Promotion of collagen synthesis and angiogenesis	[91]
Traumatic brain injury	In vivo (rats)	MSCs	Enhanced neurological recovery/increased angiogenesis and neurogenesis	[92]
HIV infection	In vitro	Breast milk	Inhibition of infection of monocyte-derived DCs	[93]
Endotoxin-induced lung injury	In vivo (mice)	MSCs	Reduced inflammatory response	[94]
Cisplatin-induced kidney injury	In vitro/in vivo (rats)	Human umbilical cord MSCs	Reduced cell injury/increased cell proliferation	[95]
Brain tumor	In vivo (rats)	MSCs	Reduced glioma growth	[96]
Liver fibrosis	In vitro	Human umbilical cord MSCs	Reduced liver fibrosis	[97]
Sepsis	In vivo (rats)	DCs	Decreased release of cytokines/reduced mortality	[98]
Arthritis	In vivo (mice)	Modified DCs	Anti-inflammatory actions	[99]

This list is not intended to be complete. It reflects a selection of studies based on their influences on the development of this field.

Abbreviations: ALS, amyotrophic lateral sclerosis; BM, bone marrow; CTx, chemotherapy; DCs, dendritic cells; EPCs, Endothelial progenitor cells; HIV, human immunodeficiency virus; MSCs, mesenchymal stem cells; POF, premature ovarian failure; SOD1, superoxide dismutase.

Chopp and colleagues [113] intravenously applied MSC-EVs in a model of transient intraluminal middle cerebral artery occlusion. EVs were administered via tail vein injection at 24 hours post-stroke. The authors observed a significant reduction of brain injury and neurological impairment that was associated with enhanced post-ischemic neurogenesis. In the hitherto only mouse study, we studied effects of MSC-derived EVs in transient intraluminal middle cerebral artery occlusion. Using the polyethylene glycol (PEG) method EVs were enriched from MSC conditioned media. MSCs were raised from BM samples of two healthy bone marrow

donors; as serum supplement 10% human platelet lysate was used [119, 120]. MSC-EVs were administered at days 1, 3, and 5 post-stroke. The treatment enhanced neurological recovery and increased endogenous neurogenesis and angiogenesis, at the same time reversing stroke-induced peripheral immunosuppression. In a head-to-head comparison, the therapeutic potential of MSC-EVs was comparable to that of the transplanted MSCs from which the MSC-EVs were derived [112].

A more recent rat study examined the effects of MSCs combined with MSC-EVs [114], demonstrating that combined MSC

Table 3. Therapeutic application of EVs in preclinical disease models associated with ischemia

Disease condition	In vitro/in vivo	EV source/EV isolation	Key results	References
Limb ischemia	In vivo (mice)	Human-induced pluripotent stem cell-derived MSCs/UC	Promotion of angiogenesis	[100]
Myocardial ischemia ^a	In vitro	MSCs/Exo-Quick	Increased survival of cardiomyocytes	[101]
Myocardial ischemia	In vivo (rats)	MSCs/Exo-Quick	Increased angiogenesis/ reduced inflammation	[102]
Myocardial ischemia	In vivo (rats)	Umbilical cord MSCs/UC	Improved systolic function	[103]
Myocardial ischemia	In vitro/in vivo (mice)	Cardiac fibroblast-derived iPS cells/UC	Increased myocardial survival	[104]
Myocardial ischemia	In vivo (rats)	Embryonic stem cells/UC	Increased myocardial regeneration	[105]
Myocardial ischemia ^b	In vitro (rats)	Coronary perfusates after remote pre-conditioning/UC	Reduction of infarct size	[106]
Myocardial ischemia	In vitro/in vivo (rats)	Plasma from rats and humans/UC	Cardioprotection	[107]
Myocardial ischemia	In vitro	GATA-4 overexpressing MSCs/UC	Cardioprotection	[108]
Myocardial ischemia	In vitro/in vivo (rats)	MSCs/UC	Increased angiogenesis/systolic function	[109]
Myocardial ischemia	In vivo (mice)	MSCs/HPLC	Reduced infarct size	[110]
Myocardial ischemia	In vitro/in vivo (mice)	Cardiac progenitor cells/UC	Increased survival of cardiomyocytes	[111]
Myocardial ischemia	In vivo (mice)	Human embryonic stem cell-derived MSCs/HPLC	Reduction of infarct size	[49]
Stroke	In vivo (mice)	MSCs/PEG	Neurological recovery/increased angiogenesis and neurogenesis/reversal of peripheral post-ischemic immunosuppression	[112]
Stroke	In vivo (rats)	MSCs/UC	Enhanced neurological recovery/angiogenesis and neurogenesis	[113]
Stroke	In vivo (rats)	Adipose derived MSCs/UC	Reduction of infarct volume/increased neurological recovery	[114]
Stroke	In vivo (rats)	Adipose derived MSCs/miRCURY	Increased functional recovery/ neuroplasticity/white matter repair	[115]
Stroke	In vivo (rats)	MSCs/UC	Enhanced neuroplasticity/increased neurological recovery	[116]
Stroke	In vitro/in vivo (rats)	miR-133b-overexpressing MSCs/UC	Secondary EV release by astrocytes/increased neural plasticity and neurological recovery	[117]
Stroke	In vivo (mice)	Embryonic stem cells/UC	Reduction of post-stroke inflammation/ restoration of neurovascular unit	[118]

^aEVs administered in a prophylactic manner, that is, prior to ischemia.

^bEVs were given as coronary perfusates from rats exposed ischemic pre-conditioning.

Abbreviations: HPLC, high performance liquid chromatography; iPS, induced pluripotent stem cells; MSCs, mesenchymal stem cells; PEG, polyethylene glycol; UC, ultracentrifugation.

and MSC-EV delivery was superior in terms of brain protection and neurological recovery when compared with MSC transplantation or EV injection only. These studies raised the question of how therapeutic effects of EVs may be boosted by loading naïve EVs with biologically active molecules such as noncoding RNAs, which by means of EVs may safely be transported to target tissues [121]. In rats exposed to transient middle cerebral artery occlusion, increased neural plasticity and neurological recovery were noted after delivery of EVs obtained from miR-133b overexpressing MSCs when compared with EVs obtained from naïve MSCs [117]. In vitro experiments using oxygen-glucose-deprivation suggested that the enhanced action of miR-133b containing EVs may be due to stimulation of secondary EV release from astrocytes [117]. In another study, EVs harvested from MSCs transfected with a miR-17-92 cluster plasmid induced better neurological recovery when compared with EVs derived from naïve MSCs [116]. These observations stress the heterogeneity of EV actions depending on the loading of EVs with survival and plasticity promoting molecules.

CLINICAL STUDIES USING EVs IN HUMANS

Despite an increasing body of evidence demonstrating that EVs might serve as biomarkers for stroke outcome [122], there is currently no study in which EVs (and especially MSC-EVs) have therapeutically been administered to human stroke patients. According to the promising data obtained in a variety of different animal models and the very promising result of the individual treatment attempt of a GvHD patient with MSC-EVs, a number of groups now try to translate EVs into the clinics. As EVs are novel biological agents and MSC-EVs are not considered as Advanced Therapy Medicinal Products (ATMP), they provide a new class of biologicals, for whose production no concrete rules have been defined by the FDA or any other national regulatory agency, yet. To this end, experts in the field have summarized in an International Society of Extracellular Vesicles (ISEV) position paper the different therapeutic EV-application fields, discussed their regulatory status and recommended requirements to be fulfilled to translate EVs as therapeutic agents into the clinics [56].

CURRENT LIMITATIONS AND BENEFITS OF EV-BASED TREATMENT PARADIGMS

Despite their different origin and their different proposed sizes, EV subtypes could not be discriminated during isolation until now. Thus, the ISEV agreed in 2014 to name fractions proposed to contain exosomes, MVs, apoptotic bodies and/or other EV types appropriately as EV fractions [123]. Since EV fractions contain a heterogeneous mix of different EV types, care has to be taken, of how EVs are purified and characterized. As such, the application of differential centrifugation (i.e., ultracentrifugation) is hampered by a low EV output due to restricted sample volumes in comparison to other techniques like size exclusion chromatography [124]. In this sense, the recently identified observation of low density lipoprotein contamination after EV enrichment might pose a problem for the evaluation of past and future work when dealing with mechanistic approaches [125]. On the contrary, for pure therapeutic applications, contaminations might be tolerated. Despite a plethora of different enrichment techniques available, ultracentrifugation, however, remains to be the gold standard for EV enrichment, albeit other techniques such as PEG isolation provide some advantages (own unpublished observation). Consequently, the ISEV has released consensus recommendations on EV purification and characterization [123]. Still, several studies do not follow these recommendations, making it difficult to compare research outcomes. To increase the reliability of the data and to promote standardization in the field the EV-TRACK consortium was formed which defined several criteria to score EV-based studies that will hopefully be followed in the future [126].

Furthermore, caution has to be taken when interpreting studies from both the stem cell and the EV field. Comorbidities and comediations, for instance, might modulate experimental outcomes. As such recommendations—especially from the cardiologic field—have been made in order to overcome typical pitfalls of cell-based therapies [127–129]. The latter emphasize the necessity of selecting the appropriate cell type or components of the secretome depending on the endpoint chosen and the definition of the application mode, including the amount of applications, the application timing and the delivery routes, to name but a few.

As EVs lack nuclei they cannot self-replicate and thus in contrast to cells do not contain any endogenous tumorigenic potential. In addition, EVs are easier to handle and, due to their small size, they can be sterilized by filtration [56]. Thus, EV-based therapeutics provide several advantages over cellular therapeutics, resulting in a competition between several research groups to

produce MSC-EVs for the clinical setting. There are several challenges connected to this issue. On the one hand, large volumes have to be processed under good medical practice compliant conditions to obtain sufficient material to treat a patient. Then, as MSCs provide a heterogeneous cell entity, MSC-EV fractions may show varying therapeutic activities as well. Indeed, the authors detected significant differences in the cytokine profile of independent MSC-EV preparations during their own research activities [57].

CONCLUSION

The application of stem cell derived EVs, especially that of MSC-EVs, offers a great opportunity for adjuvant stroke treatment. For now, EVs appear to be safe in mammals and potentially also in man, thus avoiding putative side effects that are inherent to stem cell transplantation such as malignant stem cell transformation. Besides, tissue engineering techniques allow the usage of EVs as potent carriers for bioactive molecules, which may be used for overcoming tissue barriers such as the blood-brain barrier for targeting distinct cell populations [56]. Yet, fundamental questions as to their exact mode of action and their optimal enrichment, characterization, and storage have to be answered to optimize them for the clinical setting [56].

ACKNOWLEDGMENTS

For collaboration and general support, we thank our colleagues from the institute, as well as all collaboration partners. For the financial support of our EV research, we are grateful to the Medical Faculties of the University of Duisburg-Essen (IFORES) and the University of Goettingen, the Volkswagen Foundation, the Stem Cell Network North Rhine Westphalia, and the LeitmarktAgentur.NRW and the European Union (European Regional Development Fund 2014-2020), as well as to the European Union for the EU COST program ME-HaD (BM1202).

AUTHOR CONTRIBUTIONS

T.R.D., M.B., D.M.H., and B.G.: manuscript writing, final approval of the manuscript.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicated no potential conflicts of interest.

REFERENCES

- Campbell BC, Mitchell PJ, Kleinig TJ et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med* 2015;372:1009–1018.
- Goyal M, Demchuk AM, Menon BK et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med* 2015;372:1019–1030.
- National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* 1995;333:1581–1587.
- Indredavik B, Bakke F, Solberg R et al. Benefit of a stroke unit: A randomized controlled trial. *Stroke* 1991;22:1026–1031.
- Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med* 2008;359:1317–1329.
- Sawada M, Matsumoto M, Sawamoto K. Vascular regulation of adult neurogenesis under physiological and pathological conditions. *Front Neurosci* 2014;8:53.
- Braun SM, Jessberger S. Adult neurogenesis: Mechanisms and functional significance. *Development* 2014;141:1983–1986.
- Alvarez-Buylla A, Garcia-Verdugo JM. Neurogenesis in adult subventricular zone. *J Neurosci* 2002;22:629–634.
- Stolp HB, Molnar Z. Neurogenic niches in the brain: Help and hindrance of the barrier systems. *Front Neurosci* 2015;9:20.
- Yamashima T, Tonchev AB, Yukie M. Adult hippocampal neurogenesis in rodents and primates: Endogenous, enhanced, and engrafted. *Rev Neurosci* 2007;18:67–82.
- Yamashita T, Ninomiya M, Hernandez Acosta P et al. Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum. *J Neurosci* 2006;26:6627–6636.
- Arvidsson A, Collin T, Kirik D et al. Neuronal replacement from endogenous precursors in the adult brain after stroke. *Nat Med* 2002;8:963–970.
- Parent JM. Injury-induced neurogenesis in the adult mammalian brain. *Neuroscientist* 2003;9:261–272.

- 14 Doepfner TR, Dietz GP, El Aanbouri M et al. TAT-Bcl-x(L) improves survival of neuronal precursor cells in the lesioned striatum after focal cerebral ischemia. *Neurobiol Dis* 2009;34:87–94.
- 15 Haas S, Weidner N, Winkler J. Adult stem cell therapy in stroke. *Curr Opin Neurol* 2005;18:59–64.
- 16 Doepfner TR, Nagel F, Dietz GP et al. Tat-Hsp70-mediated neuroprotection and increased survival of neuronal precursor cells after focal cerebral ischemia in mice. *J Cereb Blood Flow Metab* 2009;29:1187–1196.
- 17 Zhang J, Chopp M. Cell-based therapy for ischemic stroke. *Exp Opin Biol Ther* 2013;13:1229–1240.
- 18 Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: Therapeutic promise and potential pitfalls of clinical translation. *Lancet Neurol* 2012;11:369–380.
- 19 Doepfner TR, Ewert TA, Tonges L et al. Transduction of neural precursor cells with TAT-heat shock protein 70 chaperone: Therapeutic potential against ischemic stroke after intrastratial and systemic transplantation. *STEM CELLS* 2012;30:1297–1310.
- 20 Bacigaluppi M, Pluchino S, Martino G et al. Neural stem/precursor cells for the treatment of ischemic stroke. *J Neurol Sci* 2008;265:73–77.
- 21 Bliss TM, Andres RH, Steinberg GK. Optimizing the success of cell transplantation therapy for stroke. *Neurobiol Dis* 2010;37:275–283.
- 22 Banerjee S, Williamson DA, Habib N et al. The potential benefit of stem cell therapy after stroke: An update. *Vasc Health Risk Manag* 2012;8:569–580.
- 23 Cheng Q, Zhang Z, Zhang S et al. Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in mouse by regulating peripheral immunoinflammation. *Brain Res* 2015;1594:293–304.
- 24 Leu S, Lin YC, Yuen CM et al. Adipose-derived mesenchymal stem cells markedly attenuate brain infarct size and improve neurological function in rats. *J Transl Med* 2010;8:63.
- 25 Du G, Liu Y, Dang M et al. Comparison of administration routes for adipose-derived stem cells in the treatment of middle cerebral artery occlusion in rats. *Acta Histochem* 2014;116:1075–1084.
- 26 Komatsu K, Honmou O, Suzuki J et al. Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia. *Brain Res* 2010;1334:84–92.
- 27 Kranz A, Wagner DC, Kamprad M et al. Transplantation of placenta-derived mesenchymal stromal cells upon experimental stroke in rats. *Brain Res* 2010;1315:128–136.
- 28 Mitkari B, Nitzsche F, Kerkela E et al. Human bone marrow mesenchymal stem/stromal cells produce efficient localization in the brain and enhanced angiogenesis after intra-arterial delivery in rats with cerebral ischemia, but this is not translated to behavioral recovery. *Behav Brain Res* 2014;259:50–59.
- 29 Zheng W, Honmou O, Miyata K et al. Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. *Brain Res* 2010;1310:8–16.
- 30 Chen J, Zhang ZG, Li Y et al. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. *Circ Res* 2003;92:692–699.
- 31 Li L, Jiang Q, Ding G et al. Effects of administration route on migration and distribution of neural progenitor cells transplanted into rats with focal cerebral ischemia, an MRI study. *J Cereb Blood Flow Metabolism* 2010;30:653–662.
- 32 Doepfner TR, El Aanbouri M, Dietz GP et al. Transplantation of TAT-Bcl-xL-transduced neural precursor cells: Long-term neuroprotection after stroke. *Neurobiol Dis* 2010;40:265–276.
- 33 Doepfner TR, Kaltwasser B, Bahr M et al. Effects of neural progenitor cells on post-stroke neurological impairment—a detailed and comprehensive analysis of behavioral tests. *Front Cell Neurosci* 2014;8:338.
- 34 Doepfner TR, Kaltwasser B, Teli MK et al. Effects of acute versus post-acute systemic delivery of neural progenitor cells on neurological recovery and brain remodeling after focal cerebral ischemia in mice. *Cell Death Dis* 2014;5:e1386.
- 35 Doepfner TR, Kaltwasser B, Teli MK et al. Post-stroke transplantation of adult subventricular zone derived neural progenitor cells - a comprehensive analysis of cell delivery routes and their underlying mechanisms. *Exp Neurol* 2015;273:45–56.
- 36 Chu K, Kim M, Park KI et al. Human neural stem cells improve sensorimotor deficits in the adult rat brain with experimental focal ischemia. *Brain Res* 2004;1016:145–153.
- 37 Diez-Tejedor E, Gutierrez-Fernandez M, Martinez-Sanchez P et al. Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: A safety assessment: A phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. *J Stroke Cerebrovasc Dis* 2014;23:2694–2700.
- 38 Moniche F, Gonzalez A, Gonzalez-Marcos JR et al. Intra-arterial bone marrow mononuclear cells in ischemic stroke: A pilot clinical trial. *Stroke* 2012;43:2242–2244.
- 39 Lee JS, Hong JM, Moon GJ et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. *STEM CELLS* 2010;28:1099–1106.
- 40 Honmou O, Houkin K, Matsunaga T et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. *Brain* 2011;134:1790–1807.
- 41 Bhasin A, Srivastava MV, Kumaran SS et al. Autologous mesenchymal stem cells in chronic stroke. *Cerebrovasc Dis Extra* 2011;1:93–104.
- 42 Bhasin A, Srivastava MV, Mohanty S et al. Stem cell therapy: A clinical trial of stroke. *Clin Neurol Neurosurg* 2013;115:1003–1008.
- 43 Doepfner TR, Hermann DM. Mesenchymal stem cells in the treatment of ischemic stroke: Progress and possibilities. *Stem Cells Cloning* 2010;3:157–163.
- 44 Chang DJ, Moon H, Lee YH et al. In vivo tracking of human neural stem cells following transplantation into a rodent model of ischemic stroke. *Int J Stem Cells* 2012;5:79–83.
- 45 Chu K, Jung KH, Kim SJ et al. Transplantation of human neural stem cells protect against ischemia in a preventive mode via hypoxia-inducible factor-1 α stabilization in the host brain. *Brain Res* 2008;1207:182–192.
- 46 Eckert MA, Vu Q, Xie K et al. Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. *J Cereb Blood Flow Metab* 2013;33:1322–1334.
- 47 Lee RH, Pulin AA, Seo MJ et al. Intravenous hmscs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. *Cell Stem Cell* 2009;5:54–63.
- 48 Zanutti L, Sarukhan A, Dander E et al. Encapsulated mesenchymal stem cells for in vivo immunomodulation. *Leukemia* 2013;27:500–503.
- 49 Lai RC, Arslan F, Lee MM et al. Exosome secreted by msc reduces myocardial ischemia/reperfusion injury. *Stem Cell Res* 2010;4:214–222.
- 50 Timmers L, Lim SK, Arslan F et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. *Stem Cell Res* 2007;1:129–137.
- 51 Gnecci M, He H, Liang OD et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. *Nat Med* 2005;11:367–368.
- 52 Gnecci M, He H, Noiseux N et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. *FASEB J* 2006;20:661–669.
- 53 Gao J, Dennis JE, Muzic RF et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. *Cells Tissues Organs* 2001;169:12–20.
- 54 Schrepfer S, Deuse T, Reichenspurner H et al. Stem cell transplantation: The lung barrier. *Transplant Proc* 2007;39:573–576.
- 55 Caplan AI, Correa D. The MSC: An injury drugstore. *Cell Stem Cell* 2011;9:11–15.
- 56 Lener T, Gimona M, Aigner L et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. *J Extracell Vesicles* 2015;4:30087.
- 57 Kordelas L, Rebmann V, Ludwig AK et al. MSC-derived exosomes: A novel tool to treat therapy-refractory graft-versus-host disease. *Leukemia* 2014;28:970–973.
- 58 Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. *STEM CELLS* 2017;35:851–858.
- 59 Bruno S, Grange C, Derigibus MC et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. *J Am Soc Nephrol* 2009;20:1053–1067.
- 60 Yanez-Mo M, Siljander PR, Andreu Z et al. Biological properties of extracellular vesicles and their physiological functions. *J Extracell Vesicles* 2015;4:27066.
- 61 Ludwig AK, Giebel B. Exosomes: Small vesicles participating in intercellular communication. *Int J Biochem Cell Biol* 2012;44:11–15.
- 62 Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and

recycling of the transferrin receptor in rat reticulocytes. *J Cell Biol* 1983;97:329–339.

63 Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor. *Cell* 1983;33:967–978.

64 Pan BT, Teng K, Wu C et al. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. *J Cell Biol* 1985;101:942–948.

65 Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. *J Cell Biol* 2013;200:373–383.

66 Kim DK, Lee J, Kim SR et al. Evpedia: A community web portal for extracellular vesicles research. *Bioinformatics* 2015;31:933–939.

67 Fais S, O’Driscoll L, Borrás FE et al. Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine. *ACS Nano* 2016;10:3886–3899.

68 Valadi H, Ekström K, Bossios A et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nature Cell Biol* 2007;9:654–659.

69 Fonseca P, Vardaki I, Occhionero A et al. Metabolic and signaling functions of cancer cell-derived extracellular vesicles. *Int Rev Cell Mol Biol* 2016;326:175–199.

70 Ratajczak J, Miekus K, Kucia M et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: Evidence for horizontal transfer of mRNA and protein delivery. *Leukemia* 2006;20:847–856.

71 Iraci N, Leonardi T, Gessler F et al. Focus on extracellular vesicles: Physiological role and signalling properties of extracellular membrane vesicles. *Int J Mol Sci* 2016;17:171.

72 Raposo G, Nijman HW, Stoorvogel W et al. B lymphocytes secrete antigen-presenting vesicles. *J Exp Med* 1996;183:1161–1172.

73 Lee M, Ban JJ, Kim KY et al. Adipose-derived stem cell exosomes alleviate pathology of amyotrophic lateral sclerosis in vitro. *Biochem Biophys Res Commun* 2016;479:434–439.

74 Qian X, Xu C, Fang S et al. Exosomal microRNAs derived from umbilical mesenchymal stem cells inhibit Hepatitis C Virus infection. *STEM CELLS TRANSLATIONAL MEDICINE* 2016;5:1190–1203.

75 Koyama Y, Ito T, Hasegawa A et al. Exosomes derived from tumor cells genetically modified to express mycobacterium tuberculosis antigen: A novel vaccine for cancer therapy. *Biotechnol Lett* 2016;38:1857–1866.

76 Zhang S, Chu WC, Lai RC et al. Exosomes derived from human embryonic mesenchymal stem cells promote osteochondral regeneration. *Osteoarthritis Cartilage* 2016;24:2135–2140.

77 Mutschelknaus L, Peters C, Winkler K et al. Exosomes derived from squamous head and neck cancer promote cell survival after ionizing radiation. *PLoS One* 2016;11:e0152213.

78 Xiao GY, Cheng CC, Chiang YS et al. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy. *Sci Rep* 2016;6:23120.

79 Jiang ZZ, Liu YM, Niu X et al. Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type 1 diabetes in rats. *Stem Cell Res Ther* 2016;7:24.

80 Qi X, Zhang J, Yuan H et al. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and osteogenesis in osteoporotic rats. *Int J Biol Sci* 2016;12:836–849.

81 Li X, Chen C, Wei L et al. Exosomes derived from endothelial progenitor cells attenuate vascular repair and accelerate reendothelialization by enhancing endothelial function. *Cytotherapy* 2016;18:253–262.

82 Li XL, Li H, Zhang M et al. Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/TREG and partly dependent on FasL/Fas pathway. *J Neuroinflammation* 2016;13:8.

83 Kim DK, Nishida H, An SY et al. Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after tbi. *Proc Natl Acad Sci USA* 2016;113:170–175.

84 Lou G, Song X, Yang F et al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. *J Hematol Oncol* 2015;8:122.

85 Yang J, Liu XX, Fan H et al. Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation, oxidative stress and apoptosis. *PLoS One* 2015;10:e0140551.

86 Ji R, Zhang B, Zhang X et al. Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. *Cell Cycle* 2015;14:2473–2483.

87 Arntz OJ, Pieters BC, Oliveira MC et al. Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models. *Mol Nutr Food Res* 2015;59:1701–1712.

88 Jarmalaviciute A, Tunaitis V, Pivoraite U et al. Exosomes from dental pulp stem cells rescue human dopaminergic neurons from 6-hydroxy-dopamine-induced apoptosis. *Cytotherapy* 2015;17:932–939.

89 Pivoraite U, Jarmalaviciute A, Tunaitis V et al. Exosomes from human dental pulp stem cells suppress carrageenan-induced acute inflammation in mice. *Inflammation* 2015;38:1933–1941.

90 Zhang B, Wu X, Zhang X et al. Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the wnt4/beta-catenin pathway. *STEM CELLS TRANSLATIONAL MEDICINE* 2015;4:513–522.

91 Zhang J, Guan J, Niu X et al. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. *J Transl Med* 2015;13:49.

92 Zhang Y, Chopp M, Meng Y et al. Effect of exosomes derived from multipotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. *J Neurosurg* 2015;122:856–867.

93 Naslund TI, Paquin-Proulx D, Paredes PT et al. Exosomes from breast milk inhibit HIV-1 infection of dendritic cells and subsequent viral transfer to CD4+ T cells. *AIDS* 2014;28:171–180.

94 Zhu YG, Feng XM, Abbott J et al. Human mesenchymal stem cell microvesicles for treatment of *Escherichia coli* endotoxin-induced acute lung injury in mice. *STEM CELLS* 2014;32:116–125.

95 Zhou Y, Xu H, Xu W et al. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. *Stem Cell Res Ther* 2013;4:34.

96 Katakowski M, Buller B, Zheng X et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. *Cancer Lett* 2013;335:201–204.

97 Li T, Yan Y, Wang B et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. *Stem Cells Dev* 2013;22:845–854.

98 Miksa M, Wu R, Dong W et al. Immature dendritic cell-derived exosomes rescue septic animals via milk fat globule epidermal growth factor-factor VIII [corrected]. *J Immunol* 2009;183:5983–5990.

99 Bianco NR, Kim SH, Ruffner MA et al. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. *Arthritis Rheum* 2009;60:380–389.

100 Hu GW, Li Q, Niu X et al. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice. *Stem Cell Res Ther* 2015;6:10.

101 Zhang Z, Yang J, Yan W et al. Pretreatment of cardiac stem cells with exosomes derived from mesenchymal stem cells enhances myocardial repair. *J Am Heart Assoc* 2016;5:e002856.

102 Teng X, Chen L, Chen W et al. Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and anti-inflammation. *Cell Physiol Biochem* 2015;37:2415–2424.

103 Zhao Y, Sun X, Cao W et al. Exosomes derived from human umbilical cord mesenchymal stem cells relieve acute myocardial ischemic injury. *Stem Cells Int* 2015;2015:761643.

104 Wang Y, Zhang L, Li Y et al. Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium. *Int J Cardiol* 2015;192:61–69.

105 Khan M, Nickoloff E, Abramova T et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. *Circ Res* 2015;117:52–64.

106 Giricz Z, Varga ZV, Baranyai T et al. Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles. *J Mol Cell Cardiol* 2014;68:75–78.

107 Vicencio JM, Yellon DM, Sivaraman V et al. Plasma exosomes protect the myocardium from ischemia-reperfusion injury. *J Am Coll Cardiol* 2015;65:1525–1536.

- 108** Yu B, Kim HW, Gong M et al. Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. *Int J Cardiol* 2015;182:349–360.
- 109** Bian S, Zhang L, Duan L et al. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. *J Mol Med* 2014;92:387–397.
- 110** Arslan F, Lai RC, Smeets MB et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3k/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. *Stem Cell Res* 2013;10:301–312.
- 111** Chen L, Wang Y, Pan Y et al. Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury. *Biochem Biophys Res Commun* 2013;431:566–571.
- 112** Doepfner TR, Herz J, Gorgens A et al. Extracellular vesicles improve post-stroke neuroregeneration and prevent post-ischemic immunosuppression. *STEM CELLS TRANSLATIONAL MEDICINE* 2015;4:1131–1143.
- 113** Xin H, Li Y, Cui Y et al. Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. *J Cereb Blood Flow Metab* 2013;33:1711–1715.
- 114** Chen KH, Chen CH, Wallace CG et al. Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke. *Oncotarget* 2016;7:74537–74556.
- 115** Otero-Ortega L, Laso-Garcia F, Gomez-de Frutos MD et al. White matter repair after extracellular vesicles administration in an experimental animal model of subcortical stroke. *Sci Rep* 2017;7:44433.
- 116** Xin H, Katakowski M, Wang F et al. MicroRNA cluster mir-17-92 cluster in exosomes enhance neuroplasticity and functional recovery after stroke in rats. *Stroke* 2017;48:747–753.
- 117** Xin H, Wang F, Li Y et al. Secondary release of exosomes from astrocytes contributes to the increase in neural plasticity and improvement of functional recovery after stroke in rats treated with exosomes harvested from microRNA 133b-overexpressing multipotent mesenchymal stromal cells. *Cell Transplant* 2017;26:243–257.
- 118** Kalani A, Chaturvedi P, Kamat PK et al. Curcumin-loaded embryonic stem cell exosomes restored neurovascular unit following ischemia-reperfusion injury. *Int J Biochem Cell Biol* 2016;79:360–369.
- 119** Hemedi H, Giebel B, Wagner W. Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. *Cytotherapy* 2014;16:170–180.
- 120** Radtke S, Giebel B, Wagner W et al. Platelet lysates and their role in cell therapy. *ISBT Sci Ser* 2014;9:193–197.
- 121** Barile L, Vassalli G. Exosomes: Therapy delivery tools and biomarkers of diseases. *Pharmacol Ther* 2017;174:63–78.
- 122** Ji Q, Ji Y, Peng J et al. Increased brain-specific mir-9 and mir-124 in the serum exosomes of acute ischemic stroke patients. *PLoS One* 2016;11:e0163645.
- 123** Lotvall J, Hill AF, Hochberg F et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the international society for extracellular vesicles. *J Extracell Vesicles* 2014;3:26913.
- 124** Baranyai T, Herczeg K, Onodi Z et al. Isolation of exosomes from blood plasma: Qualitative and quantitative comparison of ultracentrifugation and size exclusion chromatography methods. *PLoS One* 2015;10:e0145686.
- 125** Sodar BW, Kittel A, Palocz K et al. Low-density lipoprotein mimics blood plasma-derived exosomes and microvesicles during isolation and detection. *Sci Rep* 2016;6:24316.
- 126** Van Deun J, Mestdagh P, Agostinis P et al. EV-track: Transparent reporting and centralizing knowledge in extracellular vesicle research. *Nat Methods* 2017;14:228–232.
- 127** Madonna R, Van Laake LW, Davidson SM et al. Position paper of the European society of cardiology working group cellular biology of the heart: Cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. *Eur Heart J* 2016;37:1789–1798.
- 128** Ferdinandy P, Hausenloy DJ, Heusch G et al. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. *Pharmacol Rev* 2014;66:1142–1174.
- 129** Hausenloy DJ, Garcia-Dorado D, Erik Botker H et al. Novel targets and future strategies for acute cardioprotection: Position paper of the European society of cardiology working group on cellular biology of the heart. *Cardiovasc Res* 2017;113:564–585.